cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Viskasari P. Kalanjati
Contact Email
fmi@journal.unair.ac.id
Phone
-
Journal Mail Official
fmi@journal.unair.ac.id
Editorial Address
Folia Medica Indonesiana The Unit of Journal Consortium and Folia Medica Indonesiana Faculty of Medicine, Universitas Airlangga Jl. Prof. Dr. Moestopo No.47, Pacar Kembang, Kec. Tambaksari, Surabaya, Jawa Timur 60132, Indonesia
Location
Kota surabaya,
Jawa timur
INDONESIA
Folia Medica Indonesiana
Published by Universitas Airlangga
ISSN : 23558398     EISSN : 2599056X     DOI : https://doi.org/10.65346/2958-4515.2401
Core Subject : Health, Science,
Biochemistry, Genetics & Molecular Biology Health Professions Medicine & Pharmacology Neuroscience
Folia Medica Indonesiana, as indicated by its name, focuses on publishing good quality articles about research and education on health science and medicine in Indonesia. However, due to the fast growth of science and knowledge in these fields, we also welcome submitted articles from around the world, especially the ones that contain related matters from lower-middle income countries. Folia Medica Indonesiana is an open-access, peer-reviewed journal that is published online at least four times a year. The scope covers various aspects of basic medical sciences includes anatomy, physiology, pathology, microbiology, pharmacology, and molecular medicine) and clinical medicine (covers specialties like internal medicine, surgery, pediatrics, oncology, psychiatry, etc). We highlight the pathology and potential treatment of metabolic syndromes and infectious diseases. Folia Medica Indonesiana also encourages the publication of articles about health education. The scope includes, but is not limited to, articles that emphasize on preventive education on certain diseases in a community, also research report of various materials and/or methods to develop medical education. We recognize the importance of this type of articles to be published alongside the assigned topic in each of our yearly issues, to provide our readers with updated information in medical sciences’ research and education simultaneously.
Arjuna Subject : Kedokteran - Kedokteran (Lain-Lain)
Articles 12 Documents
 1   2 
Search results for , issue "Vol. 51, No. 3" : 12 Documents clear
Hyperbilirubinemia treatment of neonatus in dr. Soetomo hospital surabaya Hosea, Mellisa Kristanti; Etika, Risa; Lestari, Pudji
Folia Medica Indonesiana Vol. 51, No. 3
Publisher : Folia Medica Indonesiana

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Hyperbilirubinemia is a condition of high levels bilirubin accumulating in blood and known as jaundice, a yellow coloration of the skin, sclera and nails. Hyperbilirubinemia is a problem that often occurs in newborns. Patients with neonatal hyperbilirubinemia are treated with phototerapy and exchange transfusion. The purpose of this study was to identify the hyperbilirubinemia treatments on neonatal in Dr. Soetomo Hospital Surabaya. Medical records were used to collect information on hyperbilirubinemia status and type of treatments in 2010. Inclusion criteria were used to select samples in this study. All hyperbilirubinemia patients (100 neonates) were treated with phototherapy, in which 32% of them got the treatment for less than 24 hours; and 68% got the treatment more than 24 hours. After treatment, 100% patients cured. Hyperbilirubinemia neonates in RSUD Dr Sutomo were treated with phototherapy and the treatment was successful.
Review article: the role of eltrombopag and romiplostim as the thrombopoietin receptor agonist (tpo-ra) in treatment of idiopathic thrombocytopenic purpura (itp): what is tpo-ra, when tpo-ra is used and how to take tpo-ra? Susanto, Jefri Pratama
Folia Medica Indonesiana Vol. 51, No. 3
Publisher : Folia Medica Indonesiana

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Idiopathic thrombocytopenic purpura is a autoimmune disease characterized thrombocytopenia casued by excessive platelet destruction. However, both platelet destruction and reduced thrombopoietin level are occurred in some cases. Therefore, new management of ITP is emerged which target is to increase platelet production rate via eltrombopag or romiplostim as the thrombopoietin receptor agonist (TPO-RA). Eltrombopag is given orally while romiplostim is given subcutaneously or intravenously and dose adjustment is depend on platelet count. Both eltrombopag and romiplostim is indicated in minimal response glucocorticoid or intravenous immunoglobulin or splenetomy treatment.

Page 2 of 2 | Total Record : 12

 1   2 

Filter by Year

2016 2016


Reset
Filter By Issues
All Issue Vol. 61, No. 2 Vol. 61, No. 1 Vol. 60, No. 4 Vol. 60, No. 3 Vol. 60, No. 2 Vol. 60, No. 1 Vol. 59, No. 4 Vol. 59, No. 3 Vol. 59, No. 2 Vol. 59, No. 1 Vol. 58, No. 4 Vol. 58, No. 3 Vol. 58, No. 2 Vol. 58, No. 1 Vol. 57, No. 4 Vol. 57, No. 3 Vol. 57, No. 2 Vol. 57, No. 1 Vol. 56, No. 4 Vol. 56, No. 3 Vol. 56, No. 2 Vol. 56, No. 1 Vol. 55, No. 4 Vol. 55, No. 3 Vol. 55, No. 2 Vol. 55, No. 1 Vol. 54, No. 4 Vol. 54, No. 3 Vol. 54, No. 2 Vol. 54, No. 1 Vol. 53, No. 4 Vol. 53, No. 3 Vol. 53, No. 2 Vol. 53, No. 1 Vol. 52, No. 4 Vol. 52, No. 3 Vol. 52, No. 2 Vol. 52, No. 1 Vol. 51, No. 4 Vol. 51, No. 3 More Issue